Clinical trial NCT06500091: TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
Official title: A Multicenter, Open-Label, Single-Arm, Multi-Cohort Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB2916 Injection in Combination With Chemotherapy or in Combination With Penpulimab Injection for Solid Tumors
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Soft Tissue Sarcoma
Melanoma
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-07-15
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This project is a clinical trial on the efficacy and safety of TQB2916 injection combined with chemotherapy or penpulimab injection in solid tumors. This project is divided into two cohorts. Cohort 1 aims to explore the safety and efficacy of specific subtypes of soft tissue sarcoma in subjects; Cohort 2 aims to explore safety and efficacy in subjects with undifferentiated pleomorphic sarcoma and melanoma. A total of 54 subjects are planned to be enrolled in this project.


Eligibility criteria: Inclusion Criteria:

1. The subjects voluntarily joined this study, signed an informed consent form, and had good compliance.
2. Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1 points; The expected survival period exceeds 3 months.
3. Patients with locally advanced or unresponsive relapsed/metastatic soft tissue sarcoma and melanoma diagnosed by pathology and unable or refused surgery. Cohort 1contains the following subtypes: "dedifferentiated liposarcoma, highly differentiated liposarcoma with dedifferentiated components, leiomyosarcoma (excluding uterine leiomyosarcoma)", and cohort 2 contains undifferentiated pleomorphic sarcoma and melanoma.
4. Cohort 1: No previous history of failure of anthracycline-based chemotherapy. Cohort 2: Previously treated with standard of care.
5. Cohort 2: Previously treated.
6. According to RECIST 1.1 standard, it is confirmed that there is at least one measurable lesion.
7. The main organs are functioning well.
8. Female participants of childbearing age should agree to use contraceptive measures during the study period and within 6 months after the end of the study; Within 7 days prior to enrollment, the serum pregnancy test was negative and must be a non lactating subject; Male participants should agree to use contraceptive measures during the study period and within 6 months after the end of the study period.

Exclusion Criteria:

1. Concomitant diseases and medical history:

   1. Has experienced or currently suffers from other malignant tumors within 5 years.
   2. Unresolved toxic reactions above CommonTerminology Criteria for Adverse Events level 1 caused by any previous treatment;
   3. The research treatment began with significant surgical treatment, open biopsy, or obvious traumatic injury;
   4. Long term unhealed wounds or fractures;
   5. Arterial/venous thrombotic events that have occurred within 6 months and affect current normal function;
   6. Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;
   7. Individuals who have previously undergone splenectomy or received splenic radiotherapy within 3 months prior to enrollment;
   8. Currently present with congenital hemorrhagic or coagulation diseases, or currently undergoing treatment with warfarin;
   9. Subjects with any severe and/or uncontrolled diseases, including:

      * Blood pressure control is still not ideal after dual drug treatment;
      * Suffering from ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia; ≥ Grade 2 unstable angina pectoris;
      * Active or uncontrolled severe infection or unexplained fever\>38.5 °C;
      * Cirrhosis and active hepatitis \*;
      * Active syphilis patients;
      * Renal failure requiring hemodialysis or peritoneal dialysis;
      * Have a history of immunodeficiency;
      * Poor control of diabetes;
      * Urinary routine indicates urine protein ≥++;
      * Individuals with epilepsy who require treatment;
      * Weight\<40 kg and BMI\<18.5 kg/m2, or weight loss of ≥ 10% within 3 months.
2. Tumor related symptoms and treatment:

   1. Has received surgery, chemotherapy, radiation therapy, or other anti-cancer therapies before the start of the research treatment;
   2. Before the start of the study treatment, he received the treatment of traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National MedicalProducts Administration (NMPA) approved drug directions;
   3. Cohort 1: Previously used doxorubicin exceeding 200mg/m2;
   4. Cohort 2: Undifferentiated multidirectional sarcoma that has previously received more than 2 types of anti vascular tyrosine kinase inhibitors (TKIs), or has previously received relevant immunotherapy drugs;
   5. Previously received antibodies or fusion proteins targeting CD40;
   6. Imaging shows that the tumor invades large blood vessels or has unclear boundaries with large blood vessels, or the researcher determines that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
   7. Uncontrollable pleural effusion, pericardial effusion, or ascites that still require repeated drainage;
   8. Severe bone damage caused by tumor bone metastasis may occur in the presence or after enrollment;
   9. Uncontrollable pain related to tumor bone metastasis;
   10. There was central nervous system metastasis before enrollment.
3. Research and treatment related:

   1. History of live attenuated vaccine administration before the start of research treatment or planned live attenuated vaccine administration during the study period;
   2. There is a clear bleeding tendency or clinically significant bleeding symptoms before the first use of medication;
   3. Individuals who have experienced severe hypersensitivity reactions after using monoclonal antibodies, or who are allergic to known components of the investigational drug;
   4. Active autoimmune diseases that require systemic treatment have occurred within 2 years prior to the start of the research treatment.
   5. Diagnosed with immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy.
4. Participated in clinical trials of other anti-tumor drugs within the first 4 weeks of grouping.
5. According to the researcher's judgment, there are individuals with accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or individuals who are deemed unsuitable for enrollment due to other reasons.

Primary outcomes:
measure: Overall response rate (ORR)
timeFrame: Up to 48 weeks
measure: Progression-Free Survival (PFS)
timeFrame: Up to 48 weeks
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: Up to 2 years
measure: Duration of Response (DOR)
timeFrame: Up to 48 weeks
Other outcomes:
Locations:
city: BeiJing
country: China
facility: Cancer Hospital Chinese Academy of Medical Science
state: Beijing
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
city: Zhengzhou
country: China
facility: Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
state: Henan
city: Changsha
country: China
facility: Hunan Cancer Hospital
state: Hunan
city: Changchun
country: China
facility: Jilin Cancer Hospital
state: Jilin
city: Jinan
country: China
facility: Cancer Hospital Affiliated to Shandong First Medical University
state: Shandong
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
city: Taiyuan
country: China
facility: Shanxi Cancer Hospital
state: Shanxi
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute and Hospital
state: Tianjin
city: Ürümqi
country: China
facility: Xinjiang Medical University Affiliated Cancer Hospital
state: Xinjiang
city: Hangzhou
country: China
facility: Zhe Jiang Cancer Hospital
state: Zhejiang
Study officials:
References: